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Abstract
Introduction Preoperative chemoradiotherapy represents the
standard treatment for patients with locally advanced rectal
cancer. Unfortunately, the response of individual tumors to
multimodal treatment is not uniform and ranges from com-
plete response to complete resistance. This poses a particular
problem for patients with a priori resistant tumors because
they may be exposed to irradiation and chemotherapy, treat-
ment regimens that are both expensive and at times toxic,
without benefit. Accordingly, there is a strong need to estab-
lish molecular biomarkers that predict the response of an
individual patient’s tumor to multimodal treatment and that
indicate treatment-associated toxicities prior to therapy. Such
biomarkers may guide clinicians in choosing the best possible
treatment for each individual patient. In addition, these bio-
markers could be used to identify novel molecular targets and
thereby assist in implementing novel strategies to sensitize a
priori resistant tumors to multimodal treatment regimens.
Objective The aim of this review is to summarize recent
findings about the molecular basis of treatment resistance
and treatment toxicity in patients with rectal cancer. Whole-
genome, as well as single-biomarker or multibiomarker,
analyses and their potential implications will be highlighted.
At the end, we will outline a future vision of rectal cancer
treatment in the era of personalized medicine.
Keywords Rectalcancer.Preoperativechemoradiotherapy.
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Introduction
For rectal cancers, both surgical and nonsurgical treatment
concepts have been improved considerably over the last
decades. In this respect, the surgical concept of total meso-
rectal excision (TME) [1] and the implementation of preoper-
ative treatment regimens can be considered as cornerstones of
modern and optimized treatment for locally advanced rectal
cancer. Randomized multicenter trials independently demon-
strated that preoperative application of radiotherapy, either as
short-term radiotherapy or as long-term irradiation accompa-
nied by infusional 5-fluorouracil (5-FU), significantly
decreases the rate of local recurrence [2, 3]. Consequently,
preoperative (chemo)radiotherapy now represents the stan-
dardtreatment for patientswith locally advanced rectal cancer
in Europe and the USA [4].
With respect to long-term preoperative chemoradiother-
apy, it was soon realized that the histopathological response
to chemoradiotherapy varied tremendously from one patient
to another, ranging from complete regression to complete
resistance, and that, for many patients, the extent of regres-
sion was correlated to clinical outcome [5]. In order to
increase the response rates to preoperative chemoradiother-
apy, agents such as oxaliplatin and antibody-based regimens
have been incorporated into multimodal treatment concepts,
and these strategies are currently under extensive evaluation
[4]. However, at the same time, the inclusion of more toxic
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of these treatments [4]. In some cases, acute organ toxicity
necessitates a dose reduction or even termination of therapy.
Furthermore, any higher grade of acute toxicity impairs the
quality of life of the individual patient.
While the variability of both treatment-associated tumor
regression and toxicity from one patient to another remains a
major clinical problem, it obviously draws attention to the
important possibility to individualize rectal cancer treat-
ment. In this respect, some patients may require an intensi-
fied regimen to increase tumor response, whereas standard
5-FU-based chemoradiotherapy may be sufficient for others.
However, advancing accurate stratification is strongly de-
pendent on the identification of reliable clinical parameters
and molecular biomarkers that allow pretherapeutic stratifi-
cation with high certainty. The aim of this review is to
briefly summarize the general principles of chemoradiosen-
sitivity and to highlight recent findings about the molecular
basis of treatment response and toxicity in patients with
rectal cancer. At the end, we will discuss potential implica-
tions of these findings for an individualized treatment of
rectal cancer patients.
General principles of chemoradiosensitivity
The predominant local effects of chemoradiotherapy,
which is designed to achieve tumor cell damage, are
primarily elicited by irradiation, whereas concomitant
chemotherapy may serve as a radiosensitizer, most often
without or with only small direct effects on tumor cell
killing. The effects of chemoradiotherapy are largely the
result of DNA damage, which either occurs directly
through ionization within the DNA molecule or indirectly
from the action of chemical radicals, which are also
formed during irradiation [6, 7]. Through these mecha-
nisms, several alterations, like base damage, DNA-protein
cross-links, and single-strand or double-strand breaks, are
generated and contribute to the antitumor effects and side
effects [8].
However, as already discussed above, response to che-
moradiotherapy differs widely. In general, four major
explanations for these different sensitivities of solid tumors
have been invoked, which could be causative alone or in
combination:
1. Tumors with poor response to chemoradiotherapy often
show a high content of hypoxic cells and/or fail to
reoxygenate during fractionated multimodal treatments.
For this reason, the necessary DNA damage caused by
chemical radicals formed as a result of local ionization
is not sufficient to kill all tumor cells. In general, this
fact prevails with increasing tumor sizes including
larger hypoxic and necrotic areas with lower oxygen
pressure [9, 10].
2. It is well known that cells located in proliferating cell
cycle segments are more sensitive to chemoradiotherapy
compared to cells resting or degenerating. Therefore,
the extent of tumor regression during treatment may
be explained in part by the proportion of proliferating
cells. A higher growth fraction in solid tumors might
lead to a larger turnover rate with a higher proportion of
cell loss in comparison to normal tissues [11].
3. Varying levels of repair capacity of DNA damage
caused by chemoradiotherapy have been specified in
almost all tumor cell lines and found to correlate with
the clinical radiocurability. In other words, less curable
tumors often show a strong potential for DNA damage
recovery. A confirmation of this fact in larger clinical
trials, which could justify its use as predictive marker
for tumor response and outcome, has not been achieved
so far. This might in part be due to the fact that any
given tumor always harbors a mixed cell population,
with mitotic or resting cells and stem cells with differing
sensitivity to antineoplastic agents and irradiation-induced
damage [12].
4. There seems to be an inherent chemoradiosensitivity,
which is associated with the individual genetic sensitiv-
ity of every single patient. Assuming that all malignant
cells arise from formerly normal tissue cells, it should
thus be possible to determine the individual response to
multimodal therapies via the patient’s individual genetic
profile [13]. This fact is underlined by recent literature
clearly showing a correlation between acute organ tox-
icity, which is a measure of inherent chemoradiosensi-
tivity, and outcome for different tumor entities. For
example, overall survival in patients with inoperable
head and neck cancer was significantly associated with
treatment-related high-grade acute organ toxicity [14].
Molecular basis of chemoradiosensitivity in rectal cancer
Despite the clinical importance of preoperative chemoradio-
therapy in multimodal treatment concepts for patients with
rectal cancer, our understanding of both the genetic basis of
chemoradiosensitivity and the molecular events leading to
chemoradioresistance remains relatively sparse. Relevant
investigations that have been performed to identify molecular
biomarkers differentiating responsive and resistant tumors
will be discussed below. From a systematic point of view,
high-throughput analyses (aim: whole-genome analysis) can
be distinguished from low-throughput analyses (aim: single-
biomarker or multibiomarker analysis).
Since complex phenotypes, such as tumor responsiveness
to chemoradiotherapy, likely do not depend on the alteration
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technologies have emerged as a central tool in deciphering
the molecular basis of this clinically important phenotype
because they offer the possibility to identify genomic differ-
ences between two groups of patients. However, due to the
high number of observed genomic features, it represents a
nontrivial task to determine which of these features are
actually relevant, and this kind of analysis generally requires
a high number of patients. Therefore, in situations where
there is already prior biological knowledge pointing to a
certain biomarker of interest or when preliminary evidence
suggests the involvement of certain pathways, it can be
advantageous to focus on a single or few selected bio-
markers. Such studies, with a limited number of biomarkers
of interest, require lower case numbers in order to reach
statistical significance since correction for multiple testing,
which is mandatory for high-throughput analyses, can be
omitted [15].
Whole-genome analyses
Gene expression profiling
Expression microarrays are commonly used to comprehen-
sively interrogate complex genetic pathways and networks
[16, 17]. Consequently, several investigators have used gene
expression profiling to analyze the genetics of (colo)rectal
cancer response to chemoradiotherapy (recently reviewed by
Kuremsky et al. [18], Nannini et al. [19], and Brettingham-
Moore et al. [20]). From a systematic point of view, in
vivo studies (profiling of primary rectal cancers) need to
be examined separately from in vitro studies (profiling of
cancer cell lines).
In vivo studies In a first published report, pretherapeutic
biopsies from 30 patients with locally advanced rectal car-
cinomas were profiled using a cDNA microarray [21]. All
patients participated in the CAO/ARO/AIO-94 trial of the
German Rectal Cancer Study Group (GRCSG) [3]. Tumor
response was defined as T-level downsizing, and a set of 54
genes was found to be differentially expressed between
responsive and resistant tumors. Using a leave-one-out
cross-validation strategy, response was correctly predicted in
83% of patients. A follow-up study indicated that these genes
could also assist in predicting local recurrence and disease-
freesurvival[22].Thesedataarecurrentlybeingvalidatedina
much larger set of patients (n>200) who participated in the
CAO/ARO/AIO-04 trial of the GRCSG, treated within differ-
ent institutions. Preliminary analyses of this cohort confirm
the effectiveness of expression profiling for predicting out-
come (Gaedcke and Ghadimi, unpublished data).
Shortly thereafter, a Japanese group published a gene
expression analysis of 52 rectal cancer patients treated with
preoperative radiotherapy [23]. They reported that 33 genes
were differentially expressed between responders and non-
responders (based on histopathological regression grading
of surgically resected specimens), with a class prediction
accuracy of 88.6%.
Kim and colleagues described the identification of
261 genes that were differentially expressed between
20 partial responders to preoperative chemoradiotherapy,
based on tumor regression grading, and 11 complete
responders (defined as the training set). This set was
validated in a test set of 15 patients. The authors reported
class predictionaccuraciesof 84% (training set)and 87% (test
set), respectively [24].
Similarly, Rimkus and colleagues profiled pretherapeutic
biopsies from 43 patients with locally advanced rectal can-
cers. Using histopathologic response as endpoint for com-
parison with gene expression, they identified a 42-gene
signature [25]. In the most recent study, Brettingham-
Moore and colleagues analyzed pretherapeutic biopsies
from 51 locally advanced rectal cancers and generated gene
expression classifiers based on tumor regression grade, met-
abolic response, and UICC downstaging [26]. The sensitiv-
ity and specificity of these classifiers to predict outcome
after preoperative chemoradiotherapy centered around 82%
and 89%, respectively. Interestingly, the authors also tested
the effectiveness of previously published gene expression
signatures to predict outcome in their data set, but the results
were rather unfruitful.
It is important to note that there was only a very limited
overlap of genes from within these signatures. This could be
due to several reasons: First, there are many different ways
of defining “response” and “resistance.” Second, case
numbers were different. Third, there are differences in the
number and identity of spotted genes on the respective
microarrays. Fourth, there is the problem of high dimen-
sionality of the data. In most settings, the number of patients
is naturally limited (i.e., in the order of tens or hundreds),
while the number of measured features, i.e., gene tran-
scripts, is usually very high (in the order of thousands or
tens of thousands). It is, therefore, very likely that several
gene expression signatures exist that are able to accurately
predict the clinical outcome. This may be particularly true
since genes are often highly interrelated, and homologs or
isotypes may serve similar functions in different pathways.
In the process of selecting a gene expression signature, it is,
therefore, sometimes a matter of random choice which
genes will end up in the classification signature and which
genes will not. In the past, this has lead to enormous con-
fusion and debate in the field [27–29]. Some more recent
methods actually try to avoid this problem by guiding the
gene selection process using prior knowledge, based, for
example, on pathway and functional network databases
[30, 31].
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considerable promise to unveil the underlying complex ge-
netics of chemoradioresistance and to play a future role in
stratifying rectal cancer patients. In this respect, breast can-
cer constitutes a prominent biological precedent to demon-
strate the feasibility of using expression signatures in
clinical decision-making (proof-of-principle). For this dis-
ease entity, a prognostic signature, consisting of 70 genes,
has been established [32, 33] and subsequently extensively
validated [34, 35], resulting in the initiation of a multicenter
trial confirming the clinical effectiveness of this gene set
(“Microarray in Node-Negative Disease May Avoid Che-
motherapy” [MINDACT] trial).
In vitro studies Cancer cell lines are widely used as model
systems for target screening, drug discovery, and functional
analyses because many features of primary tumors are reca-
pitulated in derived cell lines [36–39]. Eschrich and col-
leagues were the first to report a gene expression-based
model for in vitro sensitivity of colorectal cancer cell lines
to irradiation, although their analysis only included seven
colorectal cancer cell lines [40, 41]. The remaining 41 cell
lines were derived from different entities, including breast,
ovarian, renal, prostate, and non-small cell lung cancers,
leukemia, melanoma, and tumors of the central nervous
system. Building on their own earlier work [42], the authors
integrated the respective surviving fractions of these 48 cell
lines after irradiation at 2 Gy by pretreatment gene expres-
sion profiles, KRAS and TP53 mutation status, and tissue of
origin and extracted a network of 10 signature genes. This
expression model of intrinsic radiosensitivity, which includ-
ed prominent target genes such as JUN, STAT1, and CDK1,
was subsequently validated in three cohorts of patients with
rectal, esophageal, and head and neck cancer [41].
In a similar study, Spitzner and colleagues reported the
identification of a gene expression signature for sensitivity
of colorectal cancer cell lines to chemoradiotherapy [43]. A
panel of 12 cell lines was exposed to doses of both 5-FU and
radiation that were similar to the ones used in the clinic, i.e.,
3 μM of 5-FU and 2 Gy of radiation, and the respective
surviving fractions were correlated with pretreatment gene
expression profiles. Analysis of this chemoradiosensitivity
signature revealed many genes involved in mitogen-
activated protein kinase (MAPK), insulin, and Wnt signal-
ing, cell cycle genes, and novel potential target genes such
as STAT3 or ERBB2 [43].
As already pointed out for primary tumors (see the “In
vivo studies” section), there is only a very limited overlap
between the respective in vitro sensitivity signatures. In
addition to the reasons discussed above, there are other
potential explanations. First, Spitzner and colleagues corre-
lated gene expression and sensitivity to both chemotherapy
and irradiation, while Eschrich and colleagues established a
signature of radiosensitivity. Second, Eschrich and col-
leagues included cell lines that were mismatch repair
(MMR) proficient as well as cell lines that were MMR
deficient, although these pathways are genetically different
[44, 45]. Third, Eschrich and colleagues analyzed a panel of
cell lines from various tumor entities.
Chromosomal aberrations
Chromosomal aneuploidy is a defining feature of colorectal
carcinomas [46, 47]. This is reflected by tumor- and stage-
specific genomic copy number aberrations [48], which are
virtually identical in colon and rectal cancers [49, 50].
Accordingly, it may be speculated that differences in treat-
ment responses can be correlated with differences on the
DNA level.
In one of the first studies to address this question, pre-
therapeutic biopsies from 42 patients with locally advanced
rectal cancers were analyzed using metaphase comparative
genomic hybridization (CGH). Based on downsizing of the
T-category, chromosomal gains of 7q32–q36 and 7q11–q31
as well as amplifications of 20q11–q13 were associated with
responsiveness to preoperative chemoradiotherapy [51].
However, the authors reported a high probability that these
genomic copy number changes were detected by chance,
therefore requiring independent validation in a larger patient
population and with a higher resolution. In a more recent
study, Chen and colleagues used oligonucleotide array-
based CGH to screen for chromosomal copy number alter-
ations correlated with pathologic complete response (pCR).
Analyzing DNA from 95 rectal cancers, the authors ob-
served that chromosomal loss of 15q11.1–q26.3 was asso-
ciated with non-pCR, while loss of 12p13.31 was associated
with pCR [52].
Single-biomarker and multibiomarker analyses
DNA mutations in the RAS–MAPK pathway
The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
(KRAS), a member of a large family of GTP-binding pro-
teins involved in signal transduction [53, 54], plays an
important role in colorectal carcinogenesis because a high
percentage of colorectal carcinomas are characterized by
activating mutations of this oncogene [45]. These mutations
result in the constitutive activation of the MAPK pathway.
Because preliminary evidence indicated an ability of the
RAS oncogene to enhance radioresistance in vitro [55–58],
several studies investigated the potential relevance of the
RAS–MAPK pathway for the response of primary rectal
cancers to irradiation.
Luna-Perez and colleagues correlated the response of 37
rectal cancers to preoperative chemoradiotherapy with
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61, they could show that tumors with wild-type KRAS were
more likely to be responsive than tumors with mutant KRAS.
It should be noted that the authors used irradiated tumor
tissue for their analysis, although recent evidence suggests
that preoperative multimodal treatment does not alter KRAS
mutation status [60]. In contrast, Zauber and colleagues
screened pretherapeutic biopsies from 53 patients with stage
I–III rectal cancers and detected KRAS mutations in 18
patients (34%). The presence of a KRAS mutation, however,
was not indicative of tumor regression after preoperative
chemoradiotherapy [61].
Shortly thereafter, Gaedcke and colleagues observed a
KRAS mutation frequency of 48% (n045) in pretherapeu-
tic biopsies of 94 patients with locally advanced rectal
cancers [62]. In contrast to Zauber and colleagues, these
authors specifically reported the affected codons: Twenty-
nine mutations (64%) were located in codon 12, 10 muta-
tions (22%) in codon 13, and 3 mutations (7%) each in
codons 61 and 146. The presence of none of these muta-
tions was correlated with response to preoperative chemo-
radiotherapy. However, Gaedcke et al. detected differential
sensitivities when the mutations were grouped based on
the respective amino acid exchange; G12V mutations
appeared to be associated with higher rates of tumor
regression than G13D mutations (p00.012). Most recent-
ly, Garcia-Aguilar and colleagues published their analysis
of pretherapeutic biopsies from 132 patients with locally
advanced rectal cancers and reported that KRAS mutations
were more likely in tumors from patients without pCR,
i.e., resistant tumors [63].
These conflicting data indicate that it may not be suffi-
cient to solely determine the mutation status of KRAS,b u t
rather to group patients according to the respective
nucleotide-specific amino acid exchange. This interpreta-
tion is supported by previous investigations suggesting
that the level of aggressiveness depends on the mutation
form [64, 65] and that these specific mutation forms may
activate distinct downstream targets and different onco-
genic pathways [66]. Furthermore, De Roock and col-
leagues recently reported that chemotherapy-refractory
metastatic colorectal cancers harboring a G13D KRAS
mutation were more sensitive to treatment with the epi-
dermal growth factor receptor (EGFR) inhibitor cetuximab
compared to tumors with other KRAS mutations [67]. This
was confirmed in vitro, and G12V-mutated cancer cells
were resistant to cetuximab, whereas G13D-mutated and
KRAS wild-type cancer cells were sensitive. Whether the
KRAS mutation status also influences the response of
rectal cancers to multimodal treatment concepts that in-
clude EGFR inhibitors remains elusive, particularly as the
clinical relevance of these combinations remains to be
determined [68, 69].
Single-nucleotide polymorphisms
Single-nucleotide polymorphisms (SNPs) are sites in the
genome sequence where individuals differ by a single
base [70]. The total number of these sites in the human
genome is estimated to be roughly 10 million, and these
SNPs are distributed at an overall frequency of 1 in every
300 to 1,000 base pairs [71]. Importantly, it has been demon-
strated that specific haplotypes and genetic polymorphisms
are associated with clinical phenotypes. For instance, the
presence of a G allele within the SNP rs6983267, located on
chromosome 8q24, confers an increased risk for the develop-
mentofcolorectalcancer[72–74].Duetothegrowingbodyof
evidence suggesting that genetic variation between individu-
alscanaccountfordifferencesindrugresponse[75,76],ithas
been speculated that genetic polymorphisms in genes encod-
ing drug- or radiation-related responses may influence the
individual’s response to chemoradiotherapy [77].
Most prominently, thymidylate synthase (TS) has been
analyzed in this respect, but the results are conflicting. Villa-
francaandcolleagueswerethefirsttocorrelatepolymorphisms
in the TS promoterandtumor responseto preoperative chemo-
radiotherapy. Analyzing tumor DNA from pretreatment biop-
sies of 65 patients, the authors observed that the TS genotype
was predictive for tumor downstaging following preoperative
chemoradiotherapy [78].
Terrazzino and colleagues, as well as the other investi-
gators mentioned within this section, analyzed germline
(blood) DNA from rectal cancer patients. However, there
was no correlation with histopathological tumor regression
[79]. This result has recently been confirmed by Conradi
and colleagues who also failed to demonstrate any associa-
tion between TS genotype and relevant clinical parameters
such as local response, tumor regression grading, or disease-
free and overall survival [80].
In contrast, Spindler and colleagues demonstrated that
the TS genotype had a significant impact on the rate of
complete pathological response following preoperative che-
moradiotherapy [81]. Similar results were subsequently
published by Stoehlmacher and colleagues who also
reported a correlation between TS genotype and histopatho-
logical tumor regression [82]. Data from Hur and colleagues
confirm the interpretation that SNPs within the TS enhancer
region affect the response of rectal cancers to preoperative
chemoradiotherapy [83]. Very recently, Tan and colleagues
reported the prospective use of TS genotyping to direct
preoperative chemoradiotherapy in a single-institution phase
II study [84].
As a second example, recent data indicated that germline
polymorphisms in the TGFB1 gene are associated with
quality of life-impairing acute organ toxicity in patients with
locally advanced rectal cancer. Analyzing DNA from two
independent cohorts of patients participating in the CAO/
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colleagues demonstrated that all patients carrying the TGFB1
Pro25 variant developed high-grade acute organ toxicity dur-
ing preoperative 5-FU-based chemoradiotherapy [85]. The
positive predictive value for acute toxicity in the presence of
this SNP is 100%, which highlights the potential clinical
importance of this observation.
Immunohistochemistry
A plethora of studies has been published which focused on a
single immunohistochemical marker or a combination of a
few. A comprehensive summary of these studies would
extend beyond the scope of this review, and we refer the
reader to recent comprehensive reviews [18, 86, 87]. Very
briefly, primary focus was the analysis of proteins involved
in DNA damage repair, proliferation, angiogenesis, and
apoptosis, including Ki-67, cyclin E, p21, p53, survivin,
Bcl-2, BAX, EGFR, VEGF, PCNA, XIAP, PTGS2 (COX-
2), HIF-1α, TS, and PROM1 (CD133). However, for most
marker studies, the results are conflicting and still remain
inconclusive.
Novel molecular targets for chemoradiosensitization
As discussed above, there is a clinical need to establish
molecular biomarkers that differentiate responsive and re-
sistant tumors because such biomarkers could be used pre-
therapeutically to predict the response of an individual
patient’s tumor to multimodal treatment (diagnostic ap-
proach). In addition, genes that are differentially expressed
between resistant and responsive tumors could be used to
identify novel therapeutic targets and thereby assist in
implementing novel therapeutic strategies (therapeutic ap-
proach). For instance, genes that are overexpressed in resis-
tant tumors could be repressed via RNA interference
(RNAi)-based approaches [88, 89] or using chemical/small
molecule inhibitors, potentially leading to sensitization to
chemoradiotherapy. In this context, both survivin and Tcell-
specific factor 4 (TCF4) represent two prominent and prom-
ising examples.
Survivin
The baculoviral inhibitor of apoptosis repeat-containing 5
(BIRC5), more commonly referred to as survivin, encodes
for the smallest and structurally unique member of the
inhibitors of apoptosis family of proteins [90]. Survivin is
overexpressed in a variety of human tumors, and it plays a
prominent role in regulating apoptosis, during cell division,
and during adaptation to stress.
Following up on the observation that the expression
of survivin was inversely correlated with spontaneous
and radiation-induced apoptosis [91], Rödel and col-
leagues used siRNA-mediated gene silencing to demon-
strate that inhibition of survivin sensitizes colorectal
cancer cells to radiation therapy, accompanied by in-
creased levels of G2/M phase arrest and increased levels
of DNA double-strand breaks after irradiation [92]. Very
recently, the same authors could show that survivin
rapidly accumulates in the nucleus following irradiation
where it subsequently interacts with members of the
DNA double-strand break repair machinery in order to
regulate the activity of DNA-dependent protein kinase
[93]. Because survivin inhibitors are currently being
investigated in clinical trials, future studies will ulti-
mately demonstrate whether its inhibition represents an
effective strategy for (chemo)radiosensitization [94]. In
this respect, the potential relevance of survivin for mon-
itoring response to preoperative chemoradiotherapy has
recently been confirmed by Sprenger and colleagues
w h oc o u l ds h o wt h a th i g hs u r v i v i ne x p r e s s i o ni np r e -
treatment biopsies correlated with advanced postthera-
peutical tumor and UICC stage and decreased disease-free
survival [95].
TCF4
As discussed above, Ghadimi and colleagues reported
the identification of a 54-gene signature that differenti-
ated resistant and responsive rectal cancers from patients
who had been treated with preoperative chemoradiother-
apy [21]. Interestingly, within this signature, the tran-
scription factor TCF4 was found to be significantly
overexpressed in resistant tumors. TCF4, also known
as TCF7L2, represents a key downstream effector that
mediates canonical Wnt signaling, a pathway that plays
a central role in colorectal tumorigenesis and tumor
progression [96, 97].
In order to explore the functional relevance of this over-
expression for mediating treatment resistance, Kendziorra
and colleagues recently silenced TCF4 in resistant colorectal
cancer cell lines and could show that RNAi-mediated inhi-
bition of TCF4 caused a significant radiosensitization of
colorectal cancer cells with high TCF reporter activity
(Fig. 1). Follow-up experiments revealed that the effect of
radiosensitization was associated with a G2/M phase arrest,
an impaired ability to adequately halt cell cycle progression
after irradiation, and a compromised DNA double-strand
break repair [98]. These data indicate a novel role of the
Wnt transcription factor TCF4 in mediating radioresistance
and, if further validated, suggest that TCF4 is a promising
therapeutic target.
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The genetic diversity of rectal cancer is associated with
varying responses to chemoradiotherapy, and varying toxic-
ity rates. This offers a wide range of options to pretherapeuti-
cally assess both response and toxicity for the individual
patient. Consequently, a plethora of potential biomarkers has
already been evaluated using whole-genome and single-
marker or multimarker analyses, some of which have great
potential to stratify rectal cancer patients for multimodal treat-
ment regimens and to implement targeted therapeutics
(Fig. 2).
However, there are several drawbacks of these findings
that still impede transition to routine clinical practice: First,
conflicting results were obtained by different investigators.
Second, virtually all biomarkers described to date have been
identified in retrospective studies and lack independent val-
idation in a prospective setting using standardized analytical
procedures. This represents the most challenging hurdle to
the implementation of these biomarkers, once further vali-
dated, into a clinical setting.
In this respect, the TransValid-KFO179/GRCSG-Trials
(TransValid A, TransValid B) are the first biomarker-
driven clinical trials for patients with rectal cancer (Fig. 3).
Fig. 1 RNAi-mediated
silencing of TCF4 results in
radiosensitization. TCF4 was
silenced in SW837 and SW480
cells using shRNA constructs,
and stable single-cell clones
were subsequently established.
A standard colony-forming as-
say demonstrated that silencing
of TCF4 significantly increased
the sensitivity of SW480 and
SW837 cells to clinically rele-
vant doses of X-rays
CellCycle
Angiogenesis
& Hypoxia
DNARepair
Wnt/TCF4
Signaling
RAS/MAPK
Pathway
Thymidylate
Synthase
Survivin
Apoptosis
Fig. 2 Potential pathways and
proteins regulating and
mediating resistance of rectal
cancer cells to
chemoradiotherapy
Langenbecks Arch Surg (2012) 397:543–555 549Fig. 3 Outline of the TransValid-KFO179/GRCSG-Trials (TransValid
A, TransValid B). TransValid A (validation study): 200 patients will be
t r e a t e dw i t h5 - F U - b a s e d( 1 , 0 0 0m g / m
2, 120 h continuous i.v. on
days 1–5 and 29–33) chemoradiotherapy (radiation, 28×1.8 Gy) fol-
lowed by radical surgery. Adjuvant therapy consists of either four
cycles of 5-FU (500 mg/m
2, bolus i.v. on days 1–5, repeat on
day 29) or, in selected cases based on the clinicians’ discretion, six
applications of a shortened FOLFOX regimen (folinic acid 400 mg/m
2,
2 h continuous i.v.; oxaliplatin 100 mg/m
2, 2 h continuous i.v.; 5-FU
2,400 mg/m
2, 46 h continuous i.v.; on days 1, 15, 30, 45, 60, and 75).
TransValid B (feasibility study, phase I/II): 50 patients will be treated
with chemoradiotherapy (radiation, 28×1.8 Gy; 5-FU 250 mg/m
2,
continuous i.v. on days 1–14 and 22–35; oxaliplatin, 50 mg/m
2,2h
continuous i.v. on days 1, 8, 22, and 29), followed by three applications
of a shortened FOLFOX regimen on days 1, 15, and 30 and radical
surgery
Pre-therapeutic
biomaterial
Treatment
stratification
DNA mutations, 
SNPs
Copy number 
alterations
Epigenetic
modifications
Altered mRNA 
expression
levels
Altered miRNA 
expression
levels
Altered protein 
expression
levels
Intensified,
targetedRT/CT InductionCTx
RT/CT           
(5-FU mono)
Primary
resection
Fig. 4 Future vision for the treatment of patients with locally ad-
vanced rectal cancers. Pretherapeutic patient material (tumor and nor-
mal tissue) will be subjected to multilayer genomic analyses. Based on
the results of these analyses, patients will be stratified into different
(preoperative) treatment concepts (personalized medicine)
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ated and promoted by the institutions of the GRCSG as well
as the Clinical Research Unit 179 (Klinische Forschergruppe,
KFO179), the aim of these multicenter studies is to prospec-
tively implement the validation of previously identified mo-
lecular and clinical biomarkers into a highly standardized
clinical setting. To achieve this goal, patients with locally
advanced (cUICC II/III) cancers of the lower two thirds of
t h er e c t u ma sw e l la sp a t i e n t sw i t hr e s e c t a b l es y n c h r o n o u s
liver metastases (UICC IV) can be enrolled into one of these
trialsbasedontheresponsibleclinicians’discretion.In Trans-
Valid A (“validation study”), patients are treated with
standard 5-FU-based chemoradiotherapy followed by stan-
dardized TME surgery according to the German S3 Guideline
(Fig. 3). Adjuvant chemotherapy consists of either 5-FU
monotherapy or, in selected cases based on the clinicians’
assessment, a shortened FOLFOXregimen.The aimofTrans-
Valid B (“feasibility study,” phase I/II) is to establish the
feasibility of an intensified preoperative chemoradiotherapy
regimen (radiation, 5-FU, and oxaliplatin) combined with a
shortened FOLFOX regimen prior to standardized TME sur-
gery (Fig. 3). One rationale for this approach is the fact that
today many patients do not receive, or receive limited doses
of, adjuvant chemotherapy. Ascertainment of biomaterial at
various time points is a major inclusion criterion for the
TransValid trials (Fig. 3). This biomaterial will be processed
according to previously established strict standard operating
procedures, which includes performing these experiments on
a week-by-week basis (prospective data generation).
From a personal perspective, we strongly believe that
molecular biomarkers will be implemented into clinical
decision-making in the near future. In a potential scenario,
pretherapeutic patient material from both tumor and normal
tissue will be ascertained at the initial diagnosis and sub-
jected to multilayer genomic analyses (Fig. 4). Based on the
results of these analyses (aim: prediction of both response
and toxicity), the individual patient will be stratified into
different alternative treatment concepts (personalized medi-
cine). In this setting, patients with a biomarker profile indi-
cating “responder to standard treatment” are subjected to a
low-toxicity preoperative regimen. In contrast, for patients
with a biomarker profile indicating “nonresponder to stan-
dard treatment,” a more aggressive approach is needed. For
instance, an intensified regimen could be pursued, including
the application of more effective systemic agents such as
oxaliplatin. An induction combination chemotherapy (pre-
operative chemoradiotherapy followed by chemotherapy
with sufficient dose and intensity prior to surgery) would
be another interesting option because many patients do not
receive adjuvant chemotherapy after preoperative chemo-
radiotherapy and surgical resection (either due to surgical
complications, patients’ refusal, or investigators’ discretion).
For patients predicted to be “nonresponder to standard
treatment” and to develop high acute organ toxicity, primary
surgery may be an option. With respect to novel therapeutic
target genes, there are examples of molecular targets such as
survivin and TCF4 that have the potential to be incorporated
into treatment concepts, although this requires extensive val-
idation and testing.
In any case, rectal cancer represents a prominent example
on how to individualize multimodal treatment regimens.
Once demonstrated that predictive biomarkers can be exam-
ined in a week-by-week setting with high quality and repro-
ducibility and in a cost-effective manner, and once these
biomarkers have been prospectively validated utilizing suf-
ficient patient numbers, a personalized medicine is within
reach. This holds considerable promise to improve the out-
come of patients with this disease.
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